0A45 Stock Overview
Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Moderna, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$107.64 |
| 52 Week High | US$163.13 |
| 52 Week Low | US$62.55 |
| Beta | 1.59 |
| 1 Month Change | 0.69% |
| 3 Month Change | 0.52% |
| 1 Year Change | -31.25% |
| 3 Year Change | -36.29% |
| 5 Year Change | n/a |
| Change since IPO | 85.27% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0A45 | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | 4.1% | 1.4% | -0.4% |
| 1Y | -31.2% | -29.3% | -0.7% |
Return vs Industry: 0A45 underperformed the UK Biotechs industry which returned -29.3% over the past year.
Return vs Market: 0A45 underperformed the UK Market which returned -0.7% over the past year.
Price Volatility
| 0A45 volatility | |
|---|---|
| 0A45 Average Weekly Movement | 8.7% |
| Biotechs Industry Average Movement | 7.6% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in GB Market | 11.4% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: 0A45 has not had significant price volatility in the past 3 months.
Volatility Over Time: 0A45's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of UK stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2010 | 5,600 | Stephane Bancel | www.modernatx.com |
Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics.
Moderna, Inc. Fundamentals Summary
| 0A45 fundamental statistics | |
|---|---|
| Market cap | US$40.97b |
| Earnings (TTM) | -US$4.71b |
| Revenue (TTM) | US$6.85b |
6.0x
P/S Ratio-8.7x
P/E RatioIs 0A45 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0A45 income statement (TTM) | |
|---|---|
| Revenue | US$6.85b |
| Cost of Revenue | US$9.54b |
| Gross Profit | -US$2.69b |
| Other Expenses | US$2.02b |
| Earnings | -US$4.71b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -12.31 |
| Gross Margin | -39.28% |
| Net Profit Margin | -68.84% |
| Debt/Equity Ratio | 0% |
How did 0A45 perform over the long term?
See historical performance and comparison